Orserdu for ER+/HER2- ESR1-mutated advanced breast cancer
Quick answer: Orserdu is used for ER+/HER2- ESR1-mutated advanced breast cancer as part of a selective estrogen receptor degrader (elacestrant) treatment regimen. Oral SERD that binds and degrades estrogen receptor alpha, including ESR1-mutant forms driving endocrine resistance The specific dosing for ER+/HER2- ESR1-mutated advanced breast cancer is determined by your prescriber based on individual factors.
Why is Orserdu used for ER+/HER2- ESR1-mutated advanced breast cancer?
Orserdu belongs to the Selective estrogen receptor degrader (elacestrant) class. Oral SERD that binds and degrades estrogen receptor alpha, including ESR1-mutant forms driving endocrine resistance This action makes it useful for treating or managing ER+/HER2- ESR1-mutated advanced breast cancer in patients for whom this approach is clinically appropriate.
It is one of several treatment options. Whether Orserdu is the right choice for a specific patient depends on the type and severity of ER+/HER2- ESR1-mutated advanced breast cancer, response to previous treatments, individual risk factors, and clinical guidelines.
Typical dosing for ER+/HER2- ESR1-mutated advanced breast cancer
Common adult dosing range: 345 mg once daily. The actual dose for ER+/HER2- ESR1-mutated advanced breast cancer depends on:
- Severity of the condition
- Patient's age, weight, and organ function
- Other medications being taken
- Treatment response and tolerability
For complete dosing details, see the Orserdu medicine page.
What to expect
Orserdu treatment for ER+/HER2- ESR1-mutated advanced breast cancer typically involves:
- Onset of effect: varies by indication and dose — some effects are immediate, others take days to weeks
- Treatment duration: some courses are short-term, others are long-term or lifelong depending on ER+/HER2- ESR1-mutated advanced breast cancer
- Monitoring: follow-up visits to assess response and adjust dosing
- Side-effect awareness: learning what to expect and what warrants medical attention
Alternatives to consider
If Orserdu is not appropriate or not tolerated, alternatives within the same class or different therapeutic classes may be considered. See all Selective estrogen receptor degrader (elacestrant) for related options.
When to talk to your doctor
Discuss with your prescriber if you experience:
- Inadequate symptom control on Orserdu
- Side effects affecting daily life
- New medications or supplements that may interact
- Pregnancy planning or pregnancy
- Major changes in health status
Related information
Orserdu full prescribing information · All Selective estrogen receptor degrader (elacestrant) alternatives
Frequently asked questions
How effective is Orserdu for ER+/HER2- ESR1-mutated advanced breast cancer?
Effectiveness varies by individual response, dose, and severity. Orserdu is one of several treatment options for ER+/HER2- ESR1-mutated advanced breast cancer, supported by clinical evidence within the selective estrogen receptor degrader (elacestrant) class. Discuss expected response with your prescriber.
How long do I need to take Orserdu for ER+/HER2- ESR1-mutated advanced breast cancer?
Treatment duration depends on the nature of ER+/HER2- ESR1-mutated advanced breast cancer — some treatments are short-term, others long-term or lifelong. Never stop on your own; discontinuation requires clinical guidance to avoid relapse or rebound effects.
What are the main side effects of Orserdu when used for ER+/HER2- ESR1-mutated advanced breast cancer?
Common and serious side effects are class-related and substance-specific. See the full medicine page for the complete profile. Report any unexpected effects to your prescriber.
Are there alternatives to Orserdu for ER+/HER2- ESR1-mutated advanced breast cancer?
Yes. Multiple medicines and non-drug options exist for ER+/HER2- ESR1-mutated advanced breast cancer. Alternatives within the selective estrogen receptor degrader (elacestrant) class share mechanisms; other classes may offer different approaches. Discuss with your clinician.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.